

In the Claims:

Claims 1-24 (Cancelled)

26. (Currently Amended): An isolated, recombinant polypeptide comprising a member selected from the group consisting of

- (a) the an amino acid sequence SEQ ID NO:2 comprising the sequence set forth in SEQ ID NOS:2 or 4;
- (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids contiguous of SEQ ID NO:2 amino acids that corresponds to an aligned contiguous segment of one of SEQ ID NOS:2 or 4,

wherein the immunogenic fragment isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes to a the polypeptide SEQ ID NO:2 having the sequence of one of SEQ ID NOS:2 or 4.

26. (Cancelled)

27. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the polypeptide is according to (a).

28. (Cancelled)

3 29. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the polypeptide is according to (b).

30. (Cancelled)

4  
31. (Currently Amended): The isolated, recombinant polypeptide of claim 26, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids; wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.

5  
32. (Currently Amended): The isolated, recombinant polypeptide of claim 26 consisting of, wherein the amino acid sequence of (a) is according to SEQ ID NO:2.

Claims 33-42 (Cancelled)

6  
33. (Currently Amended): An immunogenic composition comprising the isolated, recombinant polypeptide of Claim 26 and a pharmaceutically acceptable carrier.

7  
34. (Previously Presented): The immunogenic composition of Claim 33, wherein the immunogenic composition comprises at least one other *Neisseria meningitidis* antigen in addition to an antigen provided by the polypeptide.

8  
35. (Cancelled)

9  
36. (Currently Amended): A method for inducing an immune response in a mammal comprising administration of the isolated, recombinant polypeptide of Claim 26.

Claims 47-49 (Cancelled)

10  
50. (New): A fusion protein comprising the isolated, recombinant polypeptide of claim 26.

10 51. (New): An immunogenic composition comprising the isolated, recombinant polypeptide  
of claim 21. 2

11 52. (New): A fusion protein comprising the isolated, recombinant polypeptide of claim 21. 3

12 53. (New): An immunogenic composition comprising the isolated, recombinant polypeptide  
of claim 21. 3

13 54. (New): An immunogenic composition consisting of the amino acid sequence SEQ ID  
NO:2.